Safety Aspects of AAV- and Lentivirus-based Cell and Gene Therapy

10:15 AM - 11:15 AM (PDT), Thursday, June 16, 2022
During recent years, a few challenges and risks to patients have been reported emerging from viral vectors platforms that lead to integration into host genomic DNA or from high vector titers resulting in fatal toxicity side effects.
In light of these findings, we are motivated to discuss the perils and opportunities of these precision medicine modalities, with the focus on increasing safety and reducing risk by:
• Optimal vector dose
• Improving transduction protocols
• Genetic screening
• Minimizing toxic side effects to patients
Moderators
photo
Chief Technology Officer & Founder
Nexcelom Bioscience of Perkin Elmer
photo
Scientific Content Writer
PerkinElmer
Speakers
photo
Distinguished Scientist
Sanofi Genzyme
photo
Professor
University of California, Los Angeles
photo
Chief Technology Officer
Pioneering Medicines VII, Inc
photo
Dr.
Sirion Biotech Gmbh